Better Buy: Celgene Corporation vs. Bristol-Myers Squibb
By most metrics, Celgene Corporation (NASDAQ: CELG) is smaller than Bristol-Myers Squibb (NYSE: BMY). Celgene has fewer employees, lower revenue, and lower earnings than BMS does. In one key way, though, Celgene is the bigger drugmaker: Its market cap is greater by several billion dollars.
This one outlier is a result of Celgene's tremendous stock performance. Shares have soared more than 250% in the past five years compared to BMS stock's gains of around 90% during the same period. But which of these two big pharma companies is the better choice for investors now? Here's how Celgene and Bristol-Myers Squibb stack up in several key areas.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Aktie
43,94 €
-2,27 %
Die Community zeigt leichtes Interesse an Bristol-Myers Squibb mit mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 65 € für Bristol-Myers Squibb impliziert eine deutliche Steigerung um über 20% gegenüber 43.94 €.
